2025 Expert Insights: New Therapies, Trials, and Techniques

Suneel Chilukuri, MD: Updates on the Latest Cosmetic Treatments in Medical Care 

Chilukuri: “In terms of what we can do with wound healing, it's pretty remarkable. We're seeing that it’s not just about prevention and treatment, it’s about regenerative medicine, so we're just scraping the tip of the iceberg. This is my 6th year in the space of regenerative medicine, and I'm probably about a decade behind what people are doing overseas. I'm excited to see what the future brings and how we're going to be able to affect our lives, our patient’s lives, in a much more positive way, from a cellular level, not a cosmetic level.”

Jennifer Hsiao, MD: Exploring Diet and New Treatments for Hidradenitis Suppurativa

Hsiao: “I'm just excited about the therapeutic pipeline in Hidradenitis Suppurativa (HS). I'm excited. There's maybe over 40 or 50 active trials right now going on for HS, phase 2 and phase 3. I really want to be able to feel like I have a broad therapeutic armamentarium when I have that patient sitting in front of me and that they're filled with efficacious and safe options that I can talk about. My hope is that also with the push with new therapies coming into the market that this will also provide the hope that's needed for patients who maybe gave up and thought there was nothing for them, so they haven't interacted with us for a while. I'm hoping we see more patients like return to the healthcare system as well.”

Jason Hawkes, MD, MS: Looking Back on 2024, Ahead to 2025

Hawkes: “When I look ahead to 2025, what are some of the concepts that get me the most excited? I'm really excited for this space of biologics, the bispecifics. These are antibodies which can simultaneously bind to 2 signals. So, we might find diseases where binding something like IL-17A might be combined with blocking things like TNF, which might maybe help with the joints a little bit more than the skin. We're seeing this happen in in both psoriasis and also atopic dermatitis, blocking some of the key type 2 cytokines, but also blocking some of these other cytokines, like IL-18 or some of the alarmin molecules, TSLP, but we might be able to modify the disease response as well as control it. These bi-specific molecules are going to be quite interesting, as they can hit different aspects of the immune response, and this might push us into the next generation of not just skin clearance, but maybe disease modification. We know these molecules can have a little bit of challenge in terms of development. We may need higher doses of these medications to hit both targets, but it's going to be really exciting to see this develop.I'm also excited for the plethora of treatments coming in the chronic spontaneous urticaria space, but not only CSU, but also CIndU or the chronic inducible urticaria. We're seeing just a flurry of excitement in both phase 1 and phase 2 trials, as we have been onboarding for some of these studies, we're excited about the various disease mechanisms, both from blocking key intracellular signaling mechanisms inside mast cells, but also some of the external receptors, including the high affinity IGE receptor. Also things like C-kit and we're starting to tease out mechanisms of disease response, such as mast cell inhibition versus mast cell depletion. These are concepts that we're going to see how they play out clinically in our patients. I'm really looking forward to what's coming down the pipeline in 2025.”

“ARM Yourself with Knowledge": Emmy Graber, MD, MBA, Shares Insights on Acne, Rosacea, and More

Graber: “So upcoming in 2025, there's a couple things that I am really excited about as it pertains to acne and rosacea. Rosacea in particular, there's a newly FDA approved low dose minocycline for treating rosacea, and I'm excited to be able to offer that to my patients in 2025. There's also been a lot of new medications coming out and being approved for hidradenitis (suppurativa) and this is very exciting because we know that patients with that disease suffer so much, and it's great to know that there may be some new options on the horizon.”

Shanna Miranti, MPAS, PA-C, Shares Expert Acne and Pediatric Dermatology Insights

Miranti: "In 2025 I do believe that this will be a very exciting time for those of us who treat atopic dermatitis. It is one of the most exciting things to treat because we have so many wonderful options at our fingertips, especially for our pediatric patients. Whether providers would prefer to start with topical therapy, or whether your patients may have moderate to severe atopic dermatitis and really need something to help from the inside out, we have a wonderful amount of options in our bag at the moment, which is really fantastic."